FAQ

Do you have a question about MGC Pharmaceuticals? Click below to read the answers to our most frequently asked questions, or contact us for more information.

MGC Pharma products are available through special access schemes throughout multiple countries, regulations differ from country to country.  You would need to obtain a prescription from a registered doctor to access our products.

MGC Pharma has two IMP’s (Investigational Medicinal Products).  One being CannEpil® targeting drug resistant epilepsy and the other being CogniCann® targeting behavioural management of dementia and Alzheimer’s disease.

The Company’s Mercury MGC Pharma line of phytotherapeutics offer a range of products to allow medical professionals to prescribe as they see best suited for their patient.

GMP stands for Good Manufacturing Practice.  MGC holds a GMP licence and is one of the only facilities with our capacity and licensing in all of Europe. This makes MGC unique and distinct from many other companies operating in the field.

IMP stands for Investigational Medicinal Product. An IMP is a pharmaceutical substance being tested or used as a reference in a clinical trial.

Phytocannabinoids are cannabinoids derived from the cannabis plant. The most abundant phytocannabinoids found in the cannabis plant are ∆9-tetrahydrocannabinol (THC) and cannabidiol (CBD) however there are more than 100 cannabinoids identified in cannabis.

CBD and THC are naturally occurring compounds found in the resinous flower of cannabis. CBD stands for cannabidiol – it is a phytocannabinoid, which is non-psychoactive.  THC stands for ∆9-tetrahydrocannabinol – also a phytocannabinoid, which is psychoactive.